TY  - CONF
AU  - Petrić, M.
AU  - Ilić, K.
AU  - Tasić, Ljiljana
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1264
AB  - OBJECTIVES: To investigate drug use six months before (SMBP) and during preg-
nancy (DP) among Serbian pregnant women (SPW). METHODS: Pharmacy based
cross-sectional survey was conducted among SPW between March through April
2009. Specially designed questionnaire was used for collecting data on socio-demo-
graphics, health status, and drug (Rx and over the counter) use. Vitamin and iron
supplements were not included in the analysis. RESULTS: 260 SPW completed the
questionnaire. 69.6% of SPW were 25–34 years old, 75.8% lived in the city area, the
majority were high school or college graduates, and 55.4% were pregnant with their
first child. 9.4% of SPW had a chronic disease. There was not a statistically significant
decrease in the percentage of SPW taking drugs DP compared to SMBP (53.9% and
53.0%, respectively), as well as in an average number of drugs taken (1.54 o 0.73 and
1.45 o 0.66 drugs/women, respectively (range 1 to 4 before and during pregnancy)).
The most frequently used drug classes by SPW were: analgetics/antipyretics, hormones,
antiinfectives, tocolitics and anti-hypertensives (25.5%, 25.5%, 19.7%, 13.7%, and
7.3%, respectively). The most frequently used analgetic/antipyretic was paracetamol
(62.83%), while the most frequently used anti-infectives were penicillins and cepha-
losporins (77.0%). The only used tocolitics were fenoterol and hexoprenaline and the
only used hormones were dydrogesterone and progesterone. Drugs that were used
belonged to these FDA fetal risk categories B, C, and D (diazepam, alprazolam and
diclofenac in the 3 rd trimester) (52.6%, 26.3%, and 15.8% respectively). SPW did not
use drugs in the FDA category X. Before pregnancy folic acid usage was low (5.5%
PW) while during the 1st, 2nd and 3rd trimester of pregnancy usage was 69.96%,
15.05%, 5.93%, respectively. CONCLUSIONS: Differences in drug use DP and
SMBP among SPW was negligible. The most frequently used drug classes during
pregnancy were: analgetics/antipyretics, hormones, antiinfectives, tocolitics and
antihypertensives.
PB  - Elsevier
C3  - Value in Health
T1  - Drug use before and during pregnancy in republic of Serbia
VL  - 12
IS  - 7
SP  - A296
EP  - A296
DO  - 10.1016/S1098-3015(10)74452-1
ER  - 

@conference{
author = "Petrić, M. and Ilić, K. and Tasić, Ljiljana",
year = "2009",
abstract = "OBJECTIVES: To investigate drug use six months before (SMBP) and during preg-
nancy (DP) among Serbian pregnant women (SPW). METHODS: Pharmacy based
cross-sectional survey was conducted among SPW between March through April
2009. Specially designed questionnaire was used for collecting data on socio-demo-
graphics, health status, and drug (Rx and over the counter) use. Vitamin and iron
supplements were not included in the analysis. RESULTS: 260 SPW completed the
questionnaire. 69.6% of SPW were 25–34 years old, 75.8% lived in the city area, the
majority were high school or college graduates, and 55.4% were pregnant with their
first child. 9.4% of SPW had a chronic disease. There was not a statistically significant
decrease in the percentage of SPW taking drugs DP compared to SMBP (53.9% and
53.0%, respectively), as well as in an average number of drugs taken (1.54 o 0.73 and
1.45 o 0.66 drugs/women, respectively (range 1 to 4 before and during pregnancy)).
The most frequently used drug classes by SPW were: analgetics/antipyretics, hormones,
antiinfectives, tocolitics and anti-hypertensives (25.5%, 25.5%, 19.7%, 13.7%, and
7.3%, respectively). The most frequently used analgetic/antipyretic was paracetamol
(62.83%), while the most frequently used anti-infectives were penicillins and cepha-
losporins (77.0%). The only used tocolitics were fenoterol and hexoprenaline and the
only used hormones were dydrogesterone and progesterone. Drugs that were used
belonged to these FDA fetal risk categories B, C, and D (diazepam, alprazolam and
diclofenac in the 3 rd trimester) (52.6%, 26.3%, and 15.8% respectively). SPW did not
use drugs in the FDA category X. Before pregnancy folic acid usage was low (5.5%
PW) while during the 1st, 2nd and 3rd trimester of pregnancy usage was 69.96%,
15.05%, 5.93%, respectively. CONCLUSIONS: Differences in drug use DP and
SMBP among SPW was negligible. The most frequently used drug classes during
pregnancy were: analgetics/antipyretics, hormones, antiinfectives, tocolitics and
antihypertensives.",
publisher = "Elsevier",
journal = "Value in Health",
title = "Drug use before and during pregnancy in republic of Serbia",
volume = "12",
number = "7",
pages = "A296-A296",
doi = "10.1016/S1098-3015(10)74452-1"
}

Petrić, M., Ilić, K.,& Tasić, L.. (2009). Drug use before and during pregnancy in republic of Serbia. in Value in Health
Elsevier., 12(7), A296-A296.
https://doi.org/10.1016/S1098-3015(10)74452-1

Petrić M, Ilić K, Tasić L. Drug use before and during pregnancy in republic of Serbia. in Value in Health. 2009;12(7):A296-A296.
doi:10.1016/S1098-3015(10)74452-1 .

Petrić, M., Ilić, K., Tasić, Ljiljana, "Drug use before and during pregnancy in republic of Serbia" in Value in Health, 12, no. 7 (2009):A296-A296,
https://doi.org/10.1016/S1098-3015(10)74452-1 . .

TY  - CONF
AU  - Petrić, M.
AU  - Tasić, Ljiljana
AU  - Sukljević, S.
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/899
AB  - OBJECTIVES: To research the usage of over-the-counter (OTC)
nonselective non-steroidal antiinflamaroty drugs (nsNSAID)
relating to the Guidelines and the rational use of drugs in patients
with gastrointestinal (GI) diseases, morbidity and hospitalisa-
tions. METHODS: This is a retrospective study for the period
2004–2006. The source of data was the database of Public Phar-
macy Pozarevac and Public Health Centar Pozarevac, Pozarevac
(Branicevo region; 200503 inhabitans). Type of data: the number
of GI hospitalisations and the number of patients with GI dis-
eases; DDD methodology (DDD/1000 inhabitants/day) for OTC
nsNSAID. RESULTS: The number of GI disease patients was
decreased: 9636 (2004), 7982 (2005), 7806 (2006). The decrease
was 17.16% (2005) and 18.99% (2006) compared to 2004. The
number of patients who used diclofenac or other nsNSAID with
proton pump inhibitors or H2-receptor antagonists (according to
Guidelines) was increased during opserved period: 817, 931,
1187, respectively; with a great increase of 45.29% (2006 com-
pered to 2004). But, the number of GI hospitalisations was
increased with 10.18% (2005) and 15.06% (2006) related to
2004. The costs of GI hospitalisations were grown: 29.52%
(2005) and 121.32% (2006), compared to the costs in 2004.
Considering the utilisation of OTC diclofenac (the most frequent
used nsNSAID) in DDD unit, we may see an increase: 62,279;
65,983; 82,911, respectively 2004–2006. We assume that this
pharmacoepidemiology data is directly related to the increases of
hospitalisation load. CONCLUSION: There is an improvement
of rational drug usage related to Guidelines, but the increase of
GI hospitalisation and diclofenac self-medication pointed out
that this relation must be more persistent in Branicevo region. It
will be usefull to educate the patients and the pharmacists, about
the adverse drug reaction (ADR) of the nsNSAID. This way
would be the right modality to improve the rational drug usage
of nsNSAID aiming to improve the quality of life and decrease
costs.
PB  - Elsevier
C3  - Value in Health
T1  - Investigation of OTC nsNSAID rational use and gastrointestinal diseases
VL  - 10
IS  - 6
SP  - A357
EP  - A357
DO  - 10.1016/S1098-3015(10)65268-0
ER  - 

@conference{
author = "Petrić, M. and Tasić, Ljiljana and Sukljević, S.",
year = "2007",
abstract = "OBJECTIVES: To research the usage of over-the-counter (OTC)
nonselective non-steroidal antiinflamaroty drugs (nsNSAID)
relating to the Guidelines and the rational use of drugs in patients
with gastrointestinal (GI) diseases, morbidity and hospitalisa-
tions. METHODS: This is a retrospective study for the period
2004–2006. The source of data was the database of Public Phar-
macy Pozarevac and Public Health Centar Pozarevac, Pozarevac
(Branicevo region; 200503 inhabitans). Type of data: the number
of GI hospitalisations and the number of patients with GI dis-
eases; DDD methodology (DDD/1000 inhabitants/day) for OTC
nsNSAID. RESULTS: The number of GI disease patients was
decreased: 9636 (2004), 7982 (2005), 7806 (2006). The decrease
was 17.16% (2005) and 18.99% (2006) compared to 2004. The
number of patients who used diclofenac or other nsNSAID with
proton pump inhibitors or H2-receptor antagonists (according to
Guidelines) was increased during opserved period: 817, 931,
1187, respectively; with a great increase of 45.29% (2006 com-
pered to 2004). But, the number of GI hospitalisations was
increased with 10.18% (2005) and 15.06% (2006) related to
2004. The costs of GI hospitalisations were grown: 29.52%
(2005) and 121.32% (2006), compared to the costs in 2004.
Considering the utilisation of OTC diclofenac (the most frequent
used nsNSAID) in DDD unit, we may see an increase: 62,279;
65,983; 82,911, respectively 2004–2006. We assume that this
pharmacoepidemiology data is directly related to the increases of
hospitalisation load. CONCLUSION: There is an improvement
of rational drug usage related to Guidelines, but the increase of
GI hospitalisation and diclofenac self-medication pointed out
that this relation must be more persistent in Branicevo region. It
will be usefull to educate the patients and the pharmacists, about
the adverse drug reaction (ADR) of the nsNSAID. This way
would be the right modality to improve the rational drug usage
of nsNSAID aiming to improve the quality of life and decrease
costs.",
publisher = "Elsevier",
journal = "Value in Health",
title = "Investigation of OTC nsNSAID rational use and gastrointestinal diseases",
volume = "10",
number = "6",
pages = "A357-A357",
doi = "10.1016/S1098-3015(10)65268-0"
}

Petrić, M., Tasić, L.,& Sukljević, S.. (2007). Investigation of OTC nsNSAID rational use and gastrointestinal diseases. in Value in Health
Elsevier., 10(6), A357-A357.
https://doi.org/10.1016/S1098-3015(10)65268-0

Petrić M, Tasić L, Sukljević S. Investigation of OTC nsNSAID rational use and gastrointestinal diseases. in Value in Health. 2007;10(6):A357-A357.
doi:10.1016/S1098-3015(10)65268-0 .

Petrić, M., Tasić, Ljiljana, Sukljević, S., "Investigation of OTC nsNSAID rational use and gastrointestinal diseases" in Value in Health, 10, no. 6 (2007):A357-A357,
https://doi.org/10.1016/S1098-3015(10)65268-0 . .